Abrdn Physical Platinum Shares ETF vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Abrdn Physical Platinum Shares ETF trades at $15.33 (market cap $1.93B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 13.1× Abrdn Physical Platinum Shares ETF's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Abrdn Physical Platinum Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Abrdn Physical Platinum Shares ETF for 42 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| PPLT | RPRX | |
|---|---|---|
Market Cap | $1.93B | $25.27B |
Volume | 2,947,556 | 3,671,183 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $25.23 | $63.96 |
52-Week Low | $13.73 | $35.44 |
Typical Hold Time | 42 Days | 0 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
PPLT, the abrdn Physical Platinum Shares ETF, is trading at $14.78, down 4.46% with a bearish technical outlook. Moving averages and oscillators signal selling pressure, though RSI levels suggest potential oversold conditions. Recent news highlights platinum's underperformance in the precious metals rally, with technical and fundamental signals pointing to continued weakness despite historical seasonal patterns.
The outlook remains cautious with bearish momentum dominating. Investment opportunity exists for contrarian investors betting on a catch-up trade in platinum, but risks include sustained supply contango and weak relative performance versus gold and silver. Key catalysts would be renewed industrial demand or shifts in precious metals sentiment.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →